SARXION BIOLOGICS

Columbia-Yale Pitch Day

10/26/2021

SARXION BIOLOGICS

Sarx

Greek: *Σαρξ*

noun: **muscle, tissue**

Meet our Launch Team

Mark Platt

Chief Executive Officer
Recombinetics, Inc.

Themis Kyriakides

Professor of Pathology and
Biomedical Engineering
Yale University

David Lewin

Director of Business Development
Yale University

Dmytro Ustianenko

Blavatnik Fellow
Yale University

SARXION BIOLOGICS

Sarxion Biologics is a unique partnership

- 6-year collaboration
- Tested and productive partnership

- Joint NIH-SBIR award ($400,000 in funding)
- Allowed and Pending Patent Applications

- Complimentary scientific expertise
- Proprietary animal genetic editing platform
- Industry leading animal husbandry capability

YALE

+

recombinetics™

=

SARXION BIOLOGICS

Hernia repair – the most common abdominal surgical procedure

1M hernia repairs in the US annually

Over 12% of population
will experience inguinal hernia in the lifetime

$10B/annually



SARXION BIOLOGICS

Commonly used materials in standard of care

Synthetics

Medtronic

GORE

Johnson & Johnson



ULTRAPRO® Macroporous

Biologics

Strattice™ Reconstructive Tissue Matrix

BD

TELA

Strattice RTM

SARXION BIOLOGICS

Biologic hernia patch limitations





Core Weakness: Poor Tissue Integration

SARXION BIOLOGICS

Strattice™ Reconstructive Tissue Matrix

Extracellular matrix – an essential component of biologic hernia patch

Extracellular matrix (ECM):

- **Main component of the Biological Hernia Patch**
- **Consists of interconnecting protein fibers**
- **Guides tissue remodeling and rate of wound healing**



porcine skin

SARXION BIOLOGICS

Sarxion Biologics ECM material has improved integration and healing

- Knock out of TSP2 – confounding matrix protein
- Increased compatibility with host tissue
- Extensively characterized using mouse and porcine model





SARXION BIOLOGICS

Sarxion Biologics has the superior solution for hernia repair

WT



TSP2-NULL



- Faster and increased cell migration
- Increased blood vessel formation
- Reduced clotting
- Excellent biomechanical compliance
- Seamless integration with the host tissue

SARXION BIOLOGICS

Sarxion Biologics is a platform company

- Hernia patches **$300K**
- Hydrogel **$250K**
- Vascular grafts **$200K**
- Plastic surgery **$200K**
- Heart valves **$50K**

Total potential value/animal: $1M

Sarxion Biologics is a multi-indication company

SARXION BIOLOGICS

Our roadmap, accomplishments, and goals - Value to patients as soon as possible



SARXION BIOLOGICS

Sarxion Biologics timeline to the market



Raising $5M ➞ 510k Filing

SARXION BIOLOGICS

SARXION BIOLOGICS



Contact information: Mark Platt
mark.platt@recombinetics.com

ECM-modified decellularized rat small diameter vascular grafts

Unmodified



WT ECM



TSP2 KO ECM



SARXION BIOLOGICS

Sarxion Biologics ECM-modified hydrogel



WT skin hydrogel



KO skin hydrogel